Close Menu
    What's Hot

    Global Equity Release/Reverse Mortgage Primary Market on Track To Hit $56bn by 2035

    18 June 2025

    Church Mission Society Pension Scheme Joins Consolidator Clara Pensions

    17 June 2025

    The McGregor Construction (Highlands) Limited Pension Plan Completes Bulk Purchase Annuity Buy-In With Just Group

    16 June 2025
    Facebook X (Twitter) Instagram
    Instagram LinkedIn X (Twitter)
    Life Risk News
    • Home
    • Features

      Both Demand and Supply Factors Contribute to Rare Secondary Market Pullback in 2024

      12 June 2025

      Funded Reinsurance Under Scrutiny But Should Remain a Feature of the UK Pension risk Transfer Market

      12 June 2025

      Plenty of Guardrails for US Life Insurers Backing Group Annuities With Private Assets

      12 June 2025

      Liver Disease Mortality in England Continues to Worsen but General Mortality Still on a Post-Covid Downward Trend

      12 June 2025

      Q&A: Matthew Sheridan, Health Data Analytics

      12 June 2025
    • Commentary

      Life Expectancy in Breast Cancer

      12 June 2025

      The Healthy Wealthy Population of the Life Settlement Market

      12 June 2025

      UK Life Insurers to Benefit from Robust Bulk Annuity Market in 2025

      14 May 2025

      The Power of Uncorrelated Diversification During Market Volatility

      14 May 2025

      Overseeing BPA Growth Safely

      14 May 2025
    • Events
    • Magazine
    • News

      Global Equity Release/Reverse Mortgage Primary Market on Track To Hit $56bn by 2035

      18 June 2025

      Church Mission Society Pension Scheme Joins Consolidator Clara Pensions

      17 June 2025

      The McGregor Construction (Highlands) Limited Pension Plan Completes Bulk Purchase Annuity Buy-In With Just Group

      16 June 2025

      The London Waste Limited Pension Scheme Completes Bulk Purchase Annuity Buy-In with Royal London

      2 June 2025

      Morrisons Retirement Saver Plan Completes Bulk Purchase Annuity Buy-In With Aviva

      28 May 2025
    Subscribe
    Life Risk News
    Home » Mortality & Life Expectancy Trends

    Mortality & Life Expectancy Trends

    Commentary 14 June 2023Mike FasanoBy Mike Fasano
    Twitter LinkedIn Email
    Share
    Twitter LinkedIn Email

    In this paper I will discuss mortality and life expectancy trends in the 20th and 21st centuries, developments that offer the potential to extend life expectancy, and funding constraints that may limit that potential.

    20th Century:

    US life expectancy (at birth) increased steadily in the 20th century, from 48.2 years in 1900 to 76.5 years in 2000.

    – Mortality improvements in the first part of the 20th century were influenced by a reduction in childhood mortality and infectious diseases due to better sanitation and safer drinking water.

    – Mid-century improvements resulted from further decline in infectious disease associated with widespread use of antibiotics and vaccines, with benefits spread evenly across ages.

    – Late century improvements were associated with a reduction in cardiovascular mortality due to medical technology that resulted in better diagnostics (echocardiograms, cardiac MRIs, etc.) and treatments such as bypass surgery, cardiac angiography and the like, as well as blood pressure and cholesterol drugs. These improvements disproportionately benefited those over age 65.

    21st Century:

    Life expectancy continued to improve, in part due to reduced cancer mortality, from 76.5 years in 2000 to 78.9 years in 2015; but then we back tracked to a life expectancy of 76.4 years in 2022, leaving 21st century performance flat thus far. The recent decline in life expectancy was due primarily to COVID-19 related deaths, but also due to drug related accidental deaths. COVID-19 deaths are trending down now, with a significant impact on total US deaths.

    Provisional mortality data published by the National Center for Health Statistics (NCHS) reveal a decline in total US deaths from 3,464,231 in 2021 to 3,273,705 in 2022, a reduction of 190,526, or 5.5%. This drop correlates strongly with the decline in COVID-19 related deaths from 462,193 in 2021 to 244,986 in 2022, a reduction of 217,207. Details on the four major causes of death are as follows:

    Predicting the future is always dicey, but I think it is reasonable to assume some further reduction in COVID-19 mortality and, hopefully, drug related deaths as well. If so, an increase in U.S. life expectancy of up to two years in the next 3 to 5 years would be possible. The question is whether we have the potential to increase life expectancy beyond that.

    Potential Future Improvements:

    – There remains significant potential for continued improvement in cancer mortality through nano cytology-driven early detection, genetic profiling, and targeted therapies that attack increased signalling for cell growth, evasion of cell death and increased blood vessel formation associated with cancer growth. Eliminating all cancer deaths would add three to four years to life expectancy at birth – theoretically possible, but I think unlikely in our lifetimes. If we achieved half of this potential, life expectancy could possibly increase by 1.5 to two years.

    – Regenerative medicine offers potential, including

    (a) miniaturized, implantable and wearable devices that can alter electrical signals to stimulate nerve regeneration,

    (b) injectable biomaterials that can trigger desired cell responses, and

    (c) organ/tissue transplants.

    Research suggests potential for spinal cord regeneration, as well as treatment of neurocognitive disorders like ALS and dementia, and possibly even cures for diseases like diabetes. While these developments offer clear potential for morbidity improvement, the longevity potential is likely to be gradual over a time and not as dramatic as treatments that would significantly impact cardiovascular or cancer death rates.

    – Epigenetics; PAI-1 levels; diabetic medications: DNA methylation has identified plasma PAI-1 levels as a significant independent predictor of lifespan. A small cohort of an Indiana Amish community with a genetic mutation associated with lower PAI-1 levels lived about 10% longer than the rest. Medication to lower PAI-1 level is in trial phase now and could offer longevity benefits, as could medications reducing insulin resistance, such as Metformin.

    – Biologic Age; Hayflick Limit: Biologic age remains in the range of 120 years and is the ultimate cap on longevity. The Hayflick Limit has shown that cells divide freely to a predetermined number of divisions and then enter senescence, which correlates with aging. Cancer cells produce an enzyme that preserves the telomere cap at the end of DNA strands and thereby allows unlimited cell division. Biologic age could theoretically be extended IF we could replicate the cancer enzyme in other cells, but this is not likely to happen in our lifetime.

    – Ethnic Demographics: For a number of reasons, Hispanic life expectancy in the US is shorter than average, while Asian life expectancy is longer. The Hispanic percentage of population is projected to increase from 17.8% in 2016 to 27.5% in 2060, which will dampen LE extension, offset in part by an expected increase in Asian percentage from 5.7% to 9.1%.

    Funding Constraints:

    Ours is an aging population with the percentage of ≥ 65-year-olds is projected to increase from 15.2% of population in 2016 to 20.6% in 2030, while the percentage of 18 to 64-year-olds decreases from 62.0% to 58.1%. This will generate greater retirement and medical expenses with a smaller workforce to fund them. U.S. versus Russia and China tensions will keep defense spending at high levels. At the same time, with federal debt to GDP in the range of 120%, at Second World War levels, the debt service burden will be a significant drain on budgetary resources, while our borrowing potential will be constrained. The microchip revolution was the Industrial Revolution of our generation, but it has run much of its course, with no likely equivalent in the foreseeable future to generate substantial productivity increases. All things considered, it is hard to believe that there will be significant public funding available over the next decade for breakthrough longevity research to extend life expectancy.

    Mike Fasano is Senior Underwriting Consultant at Fasano Associates


    Footnotes:

    1. Ahmad FB, Cisewski JA, Xu J. Anderson RN. Provisional Mortality Data – United States, 2022. MMWR Morb Mortal Wkly Rep 2023; 72:488-492. DOI: http://dx.doi.org/10.15585/mmwr7218a3

    2. CDC. National Center for Health Statistics

    3. https://news.feinberg.northwestern.edu/2020/12/04/new-drug-connects-dots-that-clots-in-covid-19-patients

    Any views expressed in this article are those of the author(s) and do not necessarily reflect the views of Life Risk News or its publisher, the European Life Settlement Association

    2023 - June Longevity and Mortality Trends Mortality Risk Volume 2 Issue 6 - June 2023
    Share. Twitter LinkedIn Email

    Related Posts

    Life Expectancy in Breast Cancer

    12 June 2025

    The Healthy Wealthy Population of the Life Settlement Market

    12 June 2025

    UK Life Insurers to Benefit from Robust Bulk Annuity Market in 2025

    14 May 2025

    The Power of Uncorrelated Diversification During Market Volatility

    14 May 2025

    Comments are closed.

    Most Popular

    Both Demand and Supply Factors Contribute to Rare Secondary Market Pullback in 2024

    12 June 2025

    Funded Reinsurance Under Scrutiny But Should Remain a Feature of the UK Pension risk Transfer Market

    12 June 2025

    Plenty of Guardrails for US Life Insurers Backing Group Annuities With Private Assets

    12 June 2025

    Liver Disease Mortality in England Continues to Worsen but General Mortality Still on a Post-Covid Downward Trend

    12 June 2025
    Ad

    Your trusted source for capital markets participation in Life Risk

    X (Twitter) Instagram LinkedIn
    Life Risk
    • About Life Risk News
    • Get In Touch
    • Our Team
    • Copyright Notice
    • Terms and Conditions
    • Privacy Policy
    • Sitemap
    Coverage
    • Home
    • Features
    • Events
    • Commentary
    Subscribe

    Type above and press Enter to search. Press Esc to cancel.

    We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept All”, you consent to the use of ALL the cookies. However, you may visit "Cookie Settings" to provide a controlled consent.
    Cookie SettingsAccept All
    Manage consent

    Privacy Overview

    This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
    Necessary
    Always Enabled
    Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
    CookieDurationDescription
    cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
    cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
    cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
    cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
    cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
    viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
    Functional
    Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
    Performance
    Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
    Analytics
    Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
    Advertisement
    Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
    Others
    Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
    SAVE & ACCEPT